Ukutolikwa koncwadi
Uphononongo lwakutshanje malunga nokuphunyezwa kovavanyo lwe-pharmacogenetic (PGx) e-Itali, olupapashwe kwi-European Journal of Human Genetics, luchaza ngokucwangcisiweyo ukusasazwa kweenkonzo zovavanyo lwe-PGx, usetyenziso lobuchwephesha, ukuphunyezwa kweklinikhi, umahluko wengingqi, kunye neengxaki ezikhoyo e-Itali, lubonelela ngesiseko esisekelwe kubungqina bokukhuthazwa okusemgangathweni kwe-pharmacogenetics e-Itali nakwamanye amazwe aseYurophu.
I. Imvelaphi kunye nenjongo
Okwangoku, ukusetyenziswa kweteknoloji ye-PGx e-Itali kuqhekekile, ngaphandle kwendlela yokudibanisa ehlangeneyo yesizwe kunye nendlela yokuqondana. Ukuze kucaciswe imeko yovavanyo lwe-pharmacogenetic yelizwe, iqela lophando lenze uphando lwelabhoratri kuzwelonke ukususela ngoJanuwari ukuya ku-Okthobha ka-2025. Iinjongo eziphambili yayizi:
-Ukubonisa imephu yokusasazwa kunye nenkonzo yeelebhu zovavanyo lwe-pharmacogenetic e-Itali;
-Ukucacisa imisebenzi yokuvavanya, iiphaneli zezakhi zofuzo, iindlela zobugcisa, kunye nemigangatho yokutolika;
-Ukutyhila umahluko wengingqi kunye nemiqobo yokuphunyezwa, ukubonelela ngenkxaso yedatha yokumisela umgangatho kazwelonke.
II. Iziphumo eziphambili
Iimpawu ezisisiseko zeelabhoratri
Uphawu lweziko: Amaziko angama-49 athathe inxaxheba, apho ama-82% kuwo yayingamaziko karhulumente kwaye i-18% kuphela yayingamaziko abucala.
-Amasebe asebenzayo: Amasebe e-genetics yezonyango abe nenani eliphezulu (39%), kulandele amacandelo e-pathology yeklinikhi kunye ne-biochemistry (18%), kunye namasebe e-pharmacology yeklinikhi (12%).
Uvavanyo lwezicelo kunye neethagethi zezakhi zofuzo
Iimeko eziphambili zesicelo:Uvavanyo lwe-PGx e-Itali lugxile kakhulu kwi-oncology. Ama-94% (iilabhoratri ezingama-46) enze uvavanyo lwe-dihydropyrimidine dehydrogenase gene (DPYD) olunxulumene nokusetyenziswa kwe-fluoropyrimidine, kwaye ama-84% (iilabhoratri ezingama-41) enze uvavanyo lwe-uridine diphosphate glucuronosyltransferase 1A1 gene (UGT1A1) olunxulumene nokusetyenziswa kwe-irinotecan.
Ezinye iimvavanyo:Iilabhoratri ezenza uvavanyo lweejini ezinxulumene ne-azathioprine, i-clopidogrel, i-warfarin, njl. (TPMT, i-CYP2C19, i-CYP2C9, i-VKORC1, njl.njl.) bezinqabile kakhulu.
Itekhnoloji kunye nokubambelela okusemgangathweni
Icebo lokuvavanya: I-100% ye-DPYD kunye ne-97% yeemvavanyo ze-UGT1A1 yayiziimvavanyo zangaphambi konyango; i-CYP2C19 kunye ne-HLA B yayiziimvavanyo ezingaphantsi kwe-preemptive; uvavanyo lwe-CYP2D6 lwalusebenza kakhulu emva kokuba kwenzeke iimpembelelo ezimbi.
Iindlela zobugcisa:I-PCR yexesha langempela yayiyeyona ndlela isetyenziswa kakhulu; i-NGS yayisetyenziswa kakhulu ukufumanisa i-HLA B gene; phakathi kwamaziko anike ingxelo ngeziphumo, ilabhoratri enye kuphela esebenzise i-whole exome sequencing (WES).
Ukubambelela okuqhelekileyo:Inani eliphezulu leelebhu lilandele izikhokelo ze-Italian Society of Pharmacology/Italian Association of Medical Oncology (SIF/AIOM) kunye nezikhokelo ze-Clinical Pharmacogenetics Implementation Consortium (CPIC)/Dutch Pharmacogenetics Working Group (DPWG).
Ukutolikwa kweziphumo kunye nokubonisana
Ukutyikitywa kwengxelo:Iingxelo zovavanyo ezingama-65% zisayinwe ziingcali zemfuza, ezingama-31% ziingcali ze-clinical pathology/biochemistry.
Ingcaciso yeklinikhi: Ama-90% eelabhoratri anike ingcaciso, ama-73% abonise umngcipheko wetyhefu/ukungasebenzi kakuhle, kodwa ama-24% kuphela anike iingcebiso ezithile zokuthatha amayeza.
Ukubonisana ngeMithi:Yi-29% kuphela yeelabhoratri ezibonelela ngeenkonzo zokubonisana ngezonyango, kwaye ezi zibonelelwe phantse kuphela ngamasebe ezonyango - amasebe e-genetics kunye ne-pathology anikelwe ambalwa kakhulu.
Imvume enolwazi:Ama-73% eelabhoratri asebenzise imiqathango ethile okanye ngokubanzi yemvume yolwazi lwe-pharmacogenetics.
Ukusasazwa kwemimandla:Umsebenzi wovavanyo wawugxile kakhulu kumantla e-Itali. Phakathi kweelabhoratri ezinomthamo wovavanyo wonyaka ongaphezulu kwama-200, ezingama-23 zazisemantla, ezi-4 zikumbindi, kwaye ezi-6 zisemazantsi naseziqhingini - ukusasazwa kwezixhobo zovavanyo ngokwengingqi okungalinganiyo.
Umthamo wovavanyo:Ama-69% eelabhoratri ayenomthamo wovavanyo wonyaka ongaphezulu kwama-200, ama-19% ayenama-100 200.
Umgaqo-nkqubo wokubuyiselwa kwemali:Phakathi kweelabhoratri eziphandwe ngabantu, ama-73% afumene imbuyekezo epheleleyo kwiNkqubo yezeMpilo yeSizwe (i-NHS), ama-22% embuyekezo engaphelelanga, kunye nama-4% angenayo imbuyekezo. Imithetho yembuyekezo yengingqi yayingangqinelani. Okwangoku, i-Itali ayinayo ikhowudi ethile yokuhlawulisa/yokubuyisela uvavanyo lwe-pharmacogenetic, nto leyo ebangela ukudideka okukhulu ekusebenziseni kuyo yonke imimandla.
III. Ingxoxo kunye neZigqibo eziphambili
Isikhundla esiphambili kwi-oncology– Uvavanyo lwe-DPYD kunye ne-UGT1A1 luxhaphake kakhulu ngenxa yokukhuthazwa kwezikhokelo ezivela kwi-European Medicines Agency (EMA) kunye ne-Italian Medicines Agency (AIFA). Nangona kunjalo, ukusetyenziswa kovavanyo lwe-pharmacogenetic kwiindawo ezingezizo ze-oncology akwanelanga ngokupheleleyo.
Itekhnoloji engalinganiyo kunye nokutolikwa kwayo– Akukho mgangatho udibeneyo weephaneli zovavanyo, ii-reagents, izixhobo ze-bioinformatics, okanye iikhrayitheriya zokutolika, nto leyo ekhokelela ekubeni iziphumo zingathelekiswa kakuhle.
Intsebenziswano enganeleyo yezifundo ezahlukeneyo– Ukubandakanyeka okuncinci kweengcali zezonyango kunye nokungafikeleli ngokwaneleyo kwiinkonzo zokubonisana ngamayeza eklinikhi.
Ukungalingani okubalulekileyo kwengingqi– Izixhobo zovavanyo lwe-PGx zigxile kakhulu kumaziko ezonyango asemantla, apho izixhobo zinqongopheleyo kwimimandla esembindini nakumzantsi – ukusilela kwezabelo.
Inkxaso yomgaqo-nkqubo ebuthathaka– I-Itali ayinaso isakhelo sesizwe esidibeneyo sovavanyo lwe-pharmacogenetic, nto leyo ekhokelela kwinkqubo engaphelelanga epheleleyo yokubuyisela imali, ummiselo, uqeqesho, njl.
Isishwankathelo
Olu phononongo lolona vavanyo lokuqala lukazwelonke lwesimo sokuphunyezwa kwe-pharmacogenetic e-Itali. Luqinisekisa ukuba i-pharmacogenetics e-Itali iqalwe yasetyenziswa kwicandelo le-oncology, kodwa iyonke iqhekekile, ayilingani ngokwemigangatho, ayilingani ngokwemimandla, kwaye ayidibani nezifundo ezininzi. Ke ngoko, ukuseka isakhelo sokulungelelanisa sikazwelonke, ukudibanisa imigangatho yetekhnoloji kunye nokutolika, kunye nokuphucula imigaqo-nkqubo kunye noqeqesho ziimfuno zexesha elizayo ze-Itali ukuze kufezekiswe ukusetyenziswa kweklinikhi okuqhelekileyo kovavanyo lwe-pharmacogenetic, okubonelela ngereferensi ebalulekileyo kwamanye amazwe aseYurophu.
Uvavanyo lweMacro kunye nolweMicro'sIsisombululo esipheleleyo se-Pharmacogenomics ezenzekelayo
-Elula: Ukulayisha isampuli ngeetyhubhu zokuqala, ukubaleka kwesitshixo esinye, ukuzenzekela kwesampuli ukuya kwisiphumo, ukuhlanganiswa okungenamthungo neLIS/HIS.
-Ngokukhawuleza: Iziphumo ziyafumaneka kwiyure e-1 kuyo yonke le nkqubo, zikhokela ngokuchanekileyo iindlela zonyango ezenzelwe wena.
-Iguquguqukayo: Ngeqonga le-HWTS AIO800, uvavanyo lwe-PGx alusathintelwa yimida yesiza - eguquguqukayo neguquguqukayo.
-Iphelele: I-matrix yemveliso etyebileyo egubungela izifo zentliziyo kunye nemithambo yegazi, izifo zengqondo, unyango lwe-oncology, ukubeleka, i-gynecology kunye nokuzala, kunye nezinye iinkalo.
-Ukuhambelana:I-Full Automated Nucleic Acid Amplification Analyzer HWTS AIO800 kunye neenkqubo zePCR zexesha langempela ezizenzekelayo.
Isihlomelo:EzinxulumeneyoIzifoes, Amayeza Anxulumeneyo, kunye neeThagethi zoVavanyo lweMfuzo ezihambelanayo
Ixesha leposi: Meyi-11-2026